Health Care

Labcorp Holdings Inc. remains a global leader in clinical lab services, delivering high‑margin oncology, genomics, and AI‑driven diagnostics while balancing cost, quality, and payer‑driven reimbursement dynamics.

Waters Corp’s stock hits new highs—boosted by a strong pipeline, 12% revenue growth, and an “Outperform” upgrade, positioning it ahead of peers in analytical tech.

Explore Steris PLC’s steady margins, strong ROE, and infection‑prevention focus amid supply‑chain and reimbursement challenges—investors see modest upside potential.

GSK reaffirms a £30bn U.S. expansion, prioritising drug development and manufacturing to tap high‑revenue markets amid new zero‑duty trade terms.

Shanghai Fosun Pharmaceutical’s new drug approval and Pfizer partnership put it in line for early market entry, patent‑cliff protection, and strong global revenue potential.

Recordati’s Enjaymo gains traction amid EU pricing pressure, as the company balances outcome‑based contracts, supply‑chain resilience, and real‑world evidence to secure reimbursement and drive growth.

Goldman Sachs gives Mettler‑Toledo a neutral rating, noting its pivotal role in drug‑development analytics and the growing demand for precision instruments in life sciences.

Boston Scientific’s new HCSC coverage for Intracept could unlock $24.9 billion in revenue and triple its market reach, driving value‑based, same‑day outpatient care for low‑back pain.

Zimmer Biomet’s recent stock slide reflects sector volatility and investor focus on earnings, margins, and product pipeline, offering insight for cautious investors.

Grifols SA stock swings on JPMorgan’s 7% target cut vs Qatar’s 2.5% stake hike—see why investors weigh short‑term caution against long‑term growth prospects.